Liposomal GM1 - InnoMedica
Alternative Names: GM1-Gangliosid; Liposomal GM1; Liposomal monosialotetrahexosylganglioside; TALINEUREN®; TLGM-1; TLN 1; TLSG-1Latest Information Update: 02 Aug 2024
At a glance
- Originator InnoMedica
- Class Antiparkinsonians; Gangliosides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Amyotrophic lateral sclerosis; Parkinson's disease
Most Recent Events
- 02 Aug 2024 Phase-I/II clinical trials in Amyotrophic lateral sclerosis in Switzerland (IV), prior to August 2024 (InnoMedica pipeline, August 2024)
- 02 Aug 2024 Phase-I/II clinical trials in Parkinson's disease in Switzerland (IV), prior to August 2024 (InnoMedica pipeline, August 2024)
- 29 May 2024 InnoMedica Schweiz plans a phase II trial in Parkinson disease (Adjunctive treatment) in Switzerland (IV) in August 2024 (NCT06431971)